COVID-19：エーザイ､治療薬を共同開発へ：エリトランとE6011活用（動画）：
COVID-19: Eisai to develop therapeutic drug: by Eritoran､E6011：
COVID-19：卫材联合开发治疗药物：利用Elytran和E6011
ー共同研究開発契約を締結し、非臨床研究活動を開始ー
エーザイ：
COVID-19の重症化対策：
COVID-19患者では、急性呼吸窮迫症候群(ARDS)や多臓器不全などにより、重症化する例が多数報告されています。
重症化のメカニズム解明：
この重症化の過程では、血管障害の形成と増悪、さらにはサイトカインストーム*の関与が想定されています。
しかし現時点では、SARS-CoV-2感染・重症化のメカニズムが、十分に解明されていません。
エーザイ創製の薬効評価：
本共同研究ではSARS-CoV-2感染非臨床動物モデルの構築します。
既に治験実績のあるエーザイ創製の
- TLR（Toll-Like Receptor）4拮抗薬・エリトランと、
- 抗FKN (フラクタルカイン)抗体薬・E6011を、
使用した薬効評価を行います。
バイオマーカー探索：
また、SARS-CoV-2感染患者由来・臨床サンプルを使用して、バイオマーカー探索を推進します。
本共同研究を通じて、COVID-19重症化のメカニズム解明と、重症化を防ぐ薬剤の創出を目指します。
ニュースリリース：2020年 | エーザイ
https://www.eisai.co.jp/news/2020/news202062.html
Eisai: Joint Development Agreement Aiming for Drug Discovery for COVID-19 Utilizing Eritoran and E6011 Concluded
Eisai Co., Ltd.
announced today that it has entered into a joint research agreement withfour research organizations
- KAN Research Institute,
- Center for Global Health and Medicine,
- Nagasaki University,
- Yokohama City University in Japan
concerning the “Development of Therapeutics to Prevent the Aggravation of the Novel Coronavirus Infectious Disease (COVID-19)” (Grant Number: 20fk0108255),
which is a research project with Eisai as the representative research organization.
This joint research project “Development of Therapeutics for Novel Coronavirus Infectious Disease (COVID-19)”
was adopted for the second public call by the Japan Agency for Medical Research and Development (AMED) as part of its operation for promotion of the research and development of innovative treatments for emerging and re-emerging infectious diseases in fiscal year 2020.
In patients with COVID-19
due to the SARS-CoV-2 infection, severe cases such as acute respiratory distress syndrome (ARDS) and subsequent multiple organ failure have been reported.The involvement of the formation and exacerbation of vasculopathy as well as the cytokine storm* in the process of aggravation are assumed.
However, at this time, the mechanism of aggravation based on the SARS-CoV-2 infection is not fully understood.
In this collaborative research,
a non-clinical animal model of SARS-CoV-2 infection will be constructed.Additionally, TLR (Toll-Like Receptor) 4 antagonist eritoran, discovered by Eisai,
and
an anti-FKN (fractalkine) antibody E6011, discovered by Eisai’s research subsidiary KAN Research Institute,
will be evaluated. In addition, this project will promote biomarker research using clinical samples derived from SARS-CoV-2 infected patients.